Table 5 Main findings of epigenetic therapy in cervical cancer

Response rate of 38.1% with the DNA methylation inhibitor 5-aza-2-deoxycytidine plus cisplatin in advanced or recurrent cervical cancer*

Demethylation and reactivation of the expression of several tumor suppressor genes in the tumors of cervical cancer patients in a phase I trial of the DNA methylation inhibitor hydralazine

Sustained stabilization of disease in a patient with cervical cancer treated within a phase I trial of the HDAC inhibitor MS-275

Major response in a patient with cervical cancer being treated with the HDAC inhibitor valproic acid followed by a single dose of epirubicin within a phase I trial

H3 and H4 hyperacetylation as well as inhibition of deacetylase activity in the tumors of cervical cancer patients with cervical cancer in a phase I trial of the HDAC inhibitor magnesium valproate

Ongoing phase II trial of the combination of hydralazine and magnesium valproate added to cisplatin chemoradiation in FIGO stage IIIB patients